Medical device and MedTech insights, news, tips and more

Data Show Zilver PTX Leads to Fewer Complications and Shorter Hospital Stays Than Traditional Bypass Surgery 

November 20, 2019

Zilver_PTX_image

At this year’s VEITHsymposium, Dr. Marc Bosiers presented data that show that patient treatment with the Zilver PTX stent has several benefits when compared to traditional bypass surgery. The data, which were gathered from a randomized controlled trial, show that treatment with Zilver PTX results in fewer complications and shorter hospital stays for patients with peripheral artery disease (PAD).

Zilver_PTX_image

PAD affects more than 236 million people worldwide.2 Zilver PTX, Cook Medical’s paclitaxel-coated stent, is used to treat patients with PAD. To better understand the impact of Zilver PTX, Cook Medical funded a five-year physician-sponsored study called ZILVERPASS that compared the effects of treatment with Zilver PTX to traditional open prosthetic bypass surgery. The study was a randomized, multicenter trial that involved 220 patients in four countries.

The data presented at VEITHsymposium show that the procedure with Zilver PTX takes about half the time as a bypass procedure. Patients who were treated with Zilver PTX had a hospital stay that was on average five days shorter. Thirty days after the procedure, patients who were treated with Zilver PTX for long and complex lesions were 60% less likely to have complications than patients who had bypass surgery. In addition, other clinical outcomes of Zilver PTX were comparable to those of bypass surgery, according to the two-year data. This study is continuing to collect results through five years.

“Our mission with Zilver PTX — and with every product we make at Cook Medical — is to try to improve people’s lives. Cook Medical has released extensive data around Zilver PTX, and this device continues to show benefits across a wide spectrum of patients. We hope that by continuing the conversation around paclitaxel, physicians and patients can make more informed decisions,” said Mark Breedlove, vice president of Cook Medical’s Vascular division.

See Full Press Release: Data Show Zilver® PTX® Leads to Fewer Complications and Shorter Hospital Stays Than Traditional Bypass Surgery | Business Wire


Written by: Cook Medical


Legacy MedSearch has more than 30 years of combined experience recruiting in the medical device industry. We pride ourselves on our professionalism and ability to communicate quickly and honestly with all parties in the hiring process. Our clients include both blue-chip companies and innovative startups within the MedTech space. Over the past 10 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs.

We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search. We craft a personalized solution for each client and position with a focus on attracting the best possible talent in the shortest possible time frame.

Are you hiring?

Contact us to discuss partnering with Legacy MedSearch on your position.

More insights

February 21, 2024
Sparrow BioAcoustics Launches Software That Turns a Smartphone into a Stethoscope 
Learn More
October 12, 2023
Brainomix and Nanoflex Robotics to Collaborate on an AI-Assisted Robotic System for Remote Stroke Intervention
Learn More
October 10, 2023
FDA clears Intelivation Technologies new Hammerdesis™ Interphalangeal Fusion System
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.